| 1 | Large-scale seroepidemiology uncovers nephrological pathologies |
|----|---|
| 2 | in people with tau autoimmunity |
| 3 | |
| 4 | |
| 5 | Authors: |
| 6 | Andreia D. Magalhães ^{1†} , Marc Emmenegger ^{1&} , Elena De Cecco ¹ , Manfredi Carta ^{1‡} , Karl |
| 7 | Frontzek ^{1§} , Andra Chincisan ¹ , Jingjing Guo ¹ , Simone Hornemann ^{1*} , Adriano Aguzzi ^{1*} |
| 8 | |
| 9 | Affiliations: |
| 10 | ¹ Institute of Neuropathology, University of Zurich; CH-8091 Zurich, Switzerland |
| 11 | *Correspondence: <u>simone.hornemann@usz.ch</u> and <u>adriano.aguzzi@usz.ch</u> |
| 12 | [†] Present address: Department of Neurology, Inselspital, Bern University Hospital; CH-3010 |
| 13 | Bern, Switzerland |
| 14 | ^{&} Present address: Division of Medical Immunology, Department of Laboratory Medicine, Uni- |
| 15 | versity Hospital Basel; CH-4031 Basel, Switzerland |
| 16 | [‡] Present address: Institute of Neurology, University of Zurich; CH-8091 Zurich, Switzerland |
| 17 | [§] Present address: University College London, Institute of Neurology, Queen Square Brain Bank; |
| 18 | WC1N 1PJ London, United Kingdom |
| 19 | Present address: Credit Suisse; CH-8001 Zurich, Switzerland |
| 20 | |
| 21 | |
| 22 | |
| | |

23 Abstract:

Importance: Intraneuronal aggregates of the microtubule-associated protein tau play a pivotal role
in Alzheimer's disease and several other neurodegenerative syndromes. Anti-tau antibodies can
reduce pathology in mouse models of neurodegeneration and are currently being tested in humans.
Objective: To evaluate the seroprevalence of natural anti-tau autoantibodies and their potential
association with diseases.
Design: In a cross-sectional study, plasma samples from a randomized university hospital cohort

IgG autoantibodies $(\alpha \tau)$ in a miniaturized, high-throughput ELISA. Samples were included if basic

and healthy blood donors, collected from 2017 to 2020, were screened for anti-MTBD-tau plasma

32 demographic data was available and age was >18 years. Data analysis was performed from De-

cember 2017 to August 2024. Titers were defined as $-\log_{10}(EC_{50})$ values. Titers of ≥ 1.8 were clas-

34 sified as $\alpha \tau^+$.

30

Participants: Blood was obtained during routine clinical care from 32,291 patients admitted as inpatients or outpatients to any department of a university hospital, or from 8,206 healthy blood donors.

38 **Results:** High-titer $\alpha \tau^+$ samples were surprisingly prevalent, with hospital patients being three times more likely to be $\alpha \tau^+$ than healthy blood donors (4.8% vs 1.6%). $\alpha \tau$ autoantibodies ligated 39 40 selectively tau, inhibited tau aggregation in vitro, and interfered with tau detection in plasma samples. No association was found between $\alpha\tau$ autoantibodies and neurologic disorders. Instead, tau 41 42 autoreactivity showed a significant association with kidney and urinary disorders (adjusted risk ratio (RR) 1.27, 95% CI 1.10-1.45, P=0.001 and 1.40, 95% CI 1.20-1.63, P<0.001 respectively). 43 44 **Conclusions and Relevance:** While $\alpha \tau$ autoimmunity was not associated with neurologic diseases, its association with extraneural pathologies will require scrutiny in the context of anti-tau 45 46 therapies. Moreover, immunochemical plasma tau assays were confounded by at antibodies,

47 whose high prevalence may limit their usefulness as biomarker.

48

49 Main Text:

50 INTRODUCTION

51 Tau is a microtubule binding protein involved in cytoskeletal dynamics and expressed in neurons^{1,2}

⁵² and in extraneural tissues, including kidney.²⁻⁵ It plays a pivotal role in Alzheimer's disease (AD),⁶

and various syndromes collectively referred to as tauopathies.⁷ The presence of brain neurofibril-

54 lary tau tangles correlates with cognitive decline,⁸ and plasma measurements of total and phos-

55 phorylated tau have emerged as promising biomarkers for monitoring of AD progression.⁹⁻¹² More-

over, active and passive immunization with antibodies against different tau epitopes are being

57 tested in clinical trials.¹³

58 Natural autoantibodies are generated against self-antigens in the absence of external antigen stim-

⁵⁹ ulation.¹⁴ They are a normal part of the immunoglobulin repertoire and have physiological roles in

60 homeostasis and surveillance,¹⁵ but can also cause pathological autoimmunity. The study of natural

autoantibodies can inform about properties of their targets, e.g. unrecognized protective or con-

tributing roles in disease.¹⁶ Some natural autoantibodies can even cause neurological disor ders.^{17,18,19}

Anti-tau autoantibodies have been detected in plasma of patients with AD²⁰ and Parkinson's disease,²¹ but also in non-neurodegeneration controls.²² The effects, if any, of natural anti-tau autoantibodies in modulating the risk of developing neurodegenerative diseases are unknown. The study of individuals with anti-tau autoantibodies could clarify their potential as modifiers or biomarkers of disease. Here, we tested 40,497 plasma samples from healthy blood donors and from patients admitted to a university hospital in a two-sites cross-sectional study for anti-tau immunoreactivity.

71

72 METHODS

73 Study design

From December 2017 until February 2020, residual heparin plasma samples were obtained from the Department of Clinical Chemistry, University Hospital of Zurich, USZ, Switzerland. Samples were collected during routine clinical care from patients admitted either as inpatients or outpatients (age \geq 18 years) and were only included if basic demographic data was available, and an informed consent for research had been provided. From March until July 2020, EDTA plasma samples from blood donors were obtained from the Blood Donation Center of Zurich, Switzerland, according to

standard criteria of blood donation. Exclusion criteria were as reported.²³ Plasma samples were 80 biobanked locally and tested in an automated indirect microELISA (Enzyme-Linked Immuno-81 82 sorbent Assay) for natural IgG autoantibodies against the microtubule-binding-domain of tau (MTBD-tau, tauK18,²³⁻²⁵ and below). Demographic and clinical data for the hospital cohort was 83 obtained from clinical records of the USZ with follow-up until December 2021, while detailed 84 clinical data for the blood donor cohort were not available for this study. ICD-10 codes²⁶ were 85 used for clinical data assessment. AD patients were selected using ICD-10 code F00 or G30. Non-86 neurodegeneration controls were defined by the lack of any Fxx or Gxx ICD-10 codes. 87

88

89 Automated microELISA screen

High-binding 1,536-well microplates (Perkin Elmer, SpectraPlate 1536 HB) were coated with 1 90 µg/mL of recombinant MTBD-tau (37 °C, 60 min; see eMethods in Supplement 1 for MTBD-tau 91 production and purification). Plates were washed 3x with phosphate-buffered saline 0.1% 92 93 Tween®20 (PBST) using a Biotek El406 washer-dispenser and blocked with 5% milk (Migros)-94 PBST (90 min). Plasma samples were diluted 1:20 in 1% milk-PBST and dispensed into the 95 MTBD-tau-coated plates using ultrasound dispensing with an ECHO 555 Liquid Handler (Labcyte/Beckman Coulter). Each sample was tested at eight serial two-fold dilutions (1:50 to 96 97 1:6,000) using different volumes to a final volume of 3 μ L/well. Human IgG-depleted serum (MvBioSource) was used as negative and anti-tau RD4 (4-repeat isoform) mouse monoclonal an-98 tibody²⁷ (05-804 clone 1E1/A6 Merck Millipore) as positive control. Plates were incubated (120 99 100 min, room temperature (RT)) and washed 5x with PBST. Secondary antibody peroxidase Affini-101 Pure® goat anti-mouse IgG H+L (115-035-003, Jackson ImmunoResearch) at 1:2,000 dilution in 1% milk-PBST for the RD4 positive control, peroxidase AffiniPure® goat anti-human IgG Fcy-102 103 specific (109-035-098, Jackson ImmunoResearch) 1:4,000 dilution in 1% milk-PBST for the 104 plasma samples and the IgG-depleted serum negative control were dispensed into the plates using 105 a Biotek MultifloFX dispenser. Plates were incubated (60 min, RT) and washed 3x with PBST. 3,3',5,5'-Tetramethylbenzidine (TMB) Chromogen Solution for ELISA (Invitrogen) was added as 106 107 colorimetric horseradish peroxidase (HRP) substrate (3 min, RT). Finally, 0.5 M H₂SO₄ was added 108 to stop the reaction. Plates were briefly centrifuged after each dispensing step except after dispensing of TMB. Plates were read at Optical Density (OD) = 450 nm in a plate reader (Perkin Elmer, 109 110 Envision).

111

112 Competitive ELISA

113 High-binding 384-well plates (Perkin Elmer, SpectraPlate 384 HB) were coated with 4 µg/mL BT2 tau monoclonal antibody (#MN1010, Thermo Fisher) in PBS. Recombinant human tau⁴⁴¹ 114 (rPeptide) was diluted to a final concentration of 0.015 ng/mL and incubated with purified anti-tau 115 autoantibodies (Supplement 1) four-fold serially diluted (1:1.66 to 1:106.6) in 1:2 plasma under 116 rotation (500 rpm, 120 min, 37°C). Samples were transferred to BT2-coated plates and incubated 117 (45 min, RT). After washing 4x with PBST, plates were incubated (0.125 µg/mL, 45 min, RT) 118 with ab64193 (polyclonal IgG antibody; Abcam). Plates were washed 4x with PBST and incubated 119 (1:2,000 dilution, 60 min, RT) with peroxidase AffiniPure® goat anti-Rabbit IgG (H+L) (111-120 035-045, Jackson ImmunoResearch). Plates were washed 4x with PBST and 1-Step[™] Ultra TMB-121 ELISA solution (Thermo Fisher) was added (7 min, RT). After addition of 0.5 M H₂SO₄, plates 122

123 were read at OD = 450 nm in a plate reader (Perkin Elmer, Envision).

124

125 Statistical analysis

126 Antibody titers were defined as the negative logarithm half-maximal responses $(-\log_{10}(EC_{50}))$ ob-

tained by fitting the OD = 450 nm of the eight dilution points of each sample tested in the micro-

128 ELISA to a logistic regression fitter. We classified as positives samples with a cut-off of -

129 $\log_{10}(\text{EC}_{50}) \ge 1.8^{23}$ Non-informative samples (fitting error >20% -log₁₀(EC₅₀) or high background) 130 were excluded from the analysis.²³ In cases where more than one sample was available for the

131 same individual the most recent $\log_{10}(EC_{50})$ value was used.

Age is presented as median with interquartile range (IQR) and comparisons were performed using non-parametric Mann-Whitney U test. Categorized age groups and sex of positives and negatives are shown as percentages and compared using two-proportions Z-test or χ^2 test for trend in proportions. Log-binomial regression models^{28,29} using MTBD-tau autoreactivity were employed to estimate age-and-sex adjusted RRs (aRR) and 95% confidence intervals (CIs), and to investigate the association between the detection of anti-MTBD-tau IgG autoantibodies and different demographic features (Supplement 1).

- 139 Statistical significance was defined by 2-tailed P-value ≤ 0.05 . Statistical analyses and data visu-
- 140 alization were performed using R version 4.3.2 and RStudio version 1.4.1106.³⁰

141 **RESULTS**

142 Prevalence of naturally occurring plasma anti-tau autoantibodies

- 143 We designed a cross-sectional study to investigate naturally occurring plasma IgG autoantibodies
- against MTBD-tau. Plasma samples from 32,291 university hospital patients (age \geq 18 years) and
- 145 8,206 healthy blood donors were screened by miniaturized ELISA (Figure 1A).²³⁻²⁵
- 146 After exclusion of non-informative samples, 4.80% (n=1,169) of the 24,339 of hospital samples,
- 147 but only 1.58% (n=104) of 6,590 healthy donors, were $\alpha \tau^+$ (Figure 1A-C). Hence, anti-tau immu-
- 148 noreactivity was more prevalent in unselected hospital patients than in healthy individuals
- 149 (P<0.001). Demographic data was available for 4,157 of the 6,590 blood donors. Median ages
- 150 were 42 (IQR 29-54) and 55 years (IQR: 40-69) for healthy donors and hospital patients, respec-
- 151 tively (P<0.001). Of the healthy blood donors, 40.9% (n=1,698) were women, whereas for the
- hospital group, 47.7% (n=11,609) of the patients were women (P<0.001). Multivariate log-bino-
- mial regression^{29,31} adjusted for age and sex showed that hospital patients had a 2.3x higher risk than healthy donors to be $\alpha \tau^+$ (aRR 2.30, 95%CI 1.83-2.92, P<0.001, Figure 1D).
- 155 The replicability of the microELISA screen was found to be high (R^2 =0.84, P<0.001, Figure 1E).
- The replicability of the interolution screen was found to be high (K = 0.64, F < 0.001, Figure 1E).
- 156 There was no cross-reactivity to two other proteins implicated in neurodegeneration, amyloid-ß
- 157 pyroglutamate and the cellular prion protein (PrP^C).²⁴ Of 12,297 patient samples, 604 samples were
- positive against MTBD-tau and 5 against amyloid-ß pyroglutamate but none was cross-reactive

against both targets (P=1, χ^2 test) (Figure 1F), Moreover, of 13,099 patient samples, 694 were

- 160 reactive against MTBD-tau and 15 against PrP^C, but again none was cross-reactive against both
- 161 targets (P=0.734, χ^2 test) (Figure 1G)
- 162

159

163 Specificity and biological activity of $\alpha \tau^+$ samples

164 To investigate their specificity, we purified anti-tau autoantibodies by MTBD-tau affinity chromatography from four individual $\alpha \tau^+$ patients (P1-P4) and from a pool of six $\alpha \tau^+$ sample (patient_IDs: 165 J909190817, J802220975, J909190382, J90806029, J908060881 and J805040458). Purified anti-166 MTBD-tau autoantibody samples had EC₅₀ values of 0.042-14.45 µg/ml whereas the mouse anti-167 MTBD-tau antibody RD4²⁷ had EC₅₀=0.002 µg/ml (eFigure 1A in Supplement 1). In a soluble-168 competition immunoassay (eFigure 1B, Supplement 1), purified $\alpha \tau^+$ autoantibodies showed a con-169 centration-dependent binding to recombinant MTBD-tau purified by cation exchange and size ex-170 171 clusion chromatography and to a pool of 8 synthetic MTBD-tau peptides but not to albumin or an

unrelated synthetic peptide (eFigure 1C in Supplement 1). To probe for polyreactivity, purified $\alpha \tau^+$

- 173 autoantibodies were tested against several structurally unrelated autoantigens and bacterial pro-
- teins, including MTBD-tau, albumin, cardiolipin, DNA, insulin, and lipopolysaccharides (LPS).
- 175 Anti-tau autoantibodies were reactive against MTBD-tau but not against any of the other antigens
- 176 or uncoated plates (eFigure 1D in Supplement 1).
- In immunofluorescent stainings, purified $\alpha \tau$ autoantibodies co-localized to cytoplasmic EGFP-177 178 0N4RTau in SH-SY5Y cells and showed similar binding patterns to an anti-tau mouse monoclonal 179 antibody H7, but not to non-transfected cells (eFigure 1E in Supplement 1). On western blots, purified at autoantibodies detected tau-specific bands in cell lysates of SH-SY5Y cells overex-180 pressing tau^{P301L/S320F}, but not in parental (wt) SH-SY5Y cells (eFigures 1F and 2 in Supplement 181 1). Hence, the immunoreactivity of $\alpha \tau^+$ samples was highly specific for tau. All IgG subclasses 182 and both κ and λ light chains were present in $\alpha \tau^+$ patients' samples (eFigure 1G and H in Supple-183 ment 1). Epitope mapping and light-chain typing revealed a polytypic response for 23% of the $\alpha \tau^+$ 184 185 samples (eFigure 1H and I in Supplement 1).
- To investigate whether purified $\alpha \tau^+$ autoantibodies interfere with the aggregation of MTBD-tau, samples from patients P7 and P8 were tested in an *in vitro* tau aggregation assay.³² MTBD-tau aggregation was induced by heparin and shaking and monitored using Thioflavin T (ThT; eFigure 3, Supplement 1). The presence of $\alpha \tau^+$ autoantibodies reduced the plateau of the ThT fluorescence signal in the kinetic trace by about half, whereas antibodies purified by protein G affinity chromatography from an $\alpha \tau^-$ patient had no effect (eFigure 3, Supplement 1). Hence, $\alpha \tau^+$ autoantibodies inhibit MTBD-tau aggregation *in vitro*.
- Plasma tau is a promising biomarker of progression for several neurological diseases.^{9-12,33} We 193 194 examined the effects of at autoantibodies onto the performance of plasma tau immunoassays (Figure 2). Purified $\alpha \tau$ autoantibodies from 5 patients (P2-P6) were added to tau⁴⁴¹-spiked plasma. 195 After incubation, the amount of free tau⁴⁴¹ was analyzed by ELISA using commercial anti-tau 196 antibodies for capture (BT2, epitope on human tau⁴⁴¹: residues 194-198) and detection (ab64193, 197 epitope on non-phosphorylated and phosphorylated human tau⁴⁴¹ surrounding residue 262).³⁴ Pu-198 199 rified at autoantibodies P4-P6 induced a concentration-dependent impairment of detection of tau⁴⁴¹ hampering the detection of plasma-spiked tau⁴⁴¹ by approximately tenfold at higher anti-200 MTBD-tau autoantibody concentration (Figure 2B, D). In contrast, P2-P3 did not show any sig-201 nificant impairment of the detection of plasma-spiked tau⁴⁴¹. This variability of interference is 202

explained by the binding epitopes on tau⁴⁴¹. P4-P6 occupy tau residues 244 to 282 including the binding epitope of ab64193, whereas P2-P3 occupy residues 273 to 327 which are outside the epitope of ab64193 (eFigure 4 in Supplement 1). Hence, the presence of $\alpha \tau^+$ autoantibodies can interfere with the detection of plasma tau in immunoassays depending on the combination of epitopes of the patient samples and of commercial antibodies used in immunoassays.

208

209 Demographic characteristics of tau-immunoreactive patients

210 The age of $\alpha \tau^+$ patients (median: 58 years; IQR: 43-71) was significantly higher than that of $\alpha \tau^-$ (median: 55; IQR: 40-68; P < 0.001, Figure 3A). Univariate logistic regression analyses of health 211 212 records for the 24,339 hospital patients showed that the prevalence of $\alpha \tau$ immunoreactivity increased with age, from 3.9% in patients aged <29 years to 7.6% in patients aged >90 years 213 (P<0.001, Figure 3B). A log-binomial regression model^{29,35} estimated that the RR for the presence 214 of anti-MTBD-tau autoantibodies was highest for patients aged 70-99 years (RR 1.26, 95% CI 215 1.11-1.43, P<0.001, Figure 3C) and for women (RR 1.20, 95% CI 1.07-1.39, P=0.002, Figure 3C). 216 217 Due to the association of anti-MTBD-tau autoantibodies with increased age and female sex, all 218 further RRs were calculated using a multivariate log-binomial regression model adjusted for age and sex. To identify potential correlations between $\alpha \tau^+$ and specific diseases, we analyzed the ad-219 220 mission to clinical departments. The highest RRs for $\alpha \tau^+$ were found for angiology (aRR 1.84, 95% CI 1.21-2.63, P=0.002) and nephrology (aRR 1.50, 95% CI 1.16-1.89, P=0.001, Figure 3D-221 222 E), whereas no significant difference was found between the percentage of $\alpha \tau^+$ and $\alpha \tau^-$ patients 223 from the department of neurology (Figure 3D).

224

225 Neurological disorders and anti-tau autoimmunity

We next mined pseudonymized clinical diagnoses from the clinical records of the USZ pertaining to the diagnoses of 23,375 patients as represented by ICD-10 codes (Figure 4A). Given the involvement of tau in neurodegenerative diseases,⁶ we focused on evaluating the association between anti-MTBD-tau autoantibodies and neurological diseases, which we categorized in 23 main groups of disorders. No associations between $\alpha \tau^+$ and neurological diseases were identified (Figure 4A). We further performed a targeted screen using plasma samples from 47 patients with AD and 68 similarly aged non-AD patients selected from our plasma biobank (eTable 1 in Supplement 1).

233 Samples were tested for anti-MTBD-tau IgG autoantibodies, as in the primary screen, and addi-

- tionally for anti-MTBD-tau IgA autoantibodies and anti-full-length-tau IgG and IgA autoantibod-
- 235 ies. No significant difference in reactivity was observed between the plasma samples from AD
- patients and non-AD controls (Figure 4B), supporting the hypothesis that the presence of autoan-
- tibodies targeting MTBD-tau is unrelated to AD or other neurological disorders.
- 238

239 Systemic disorders and anti-tau autoimmunity

- We next assessed possible associations between tau autoimmunity and extraneural diseases, which 240 we binned into 27 main groups of disorders (Figure 5A). After adjustment for multiple compari-241 sons, $\alpha \tau$ immunoreactivity showed significant associations with vascular disorders (aRR 1.51, 95%) 242 CI 1.28-1.77, P<0.001), nutritional disorders (aRR 1.31, 95% CI 1.14-1.50, P<0.001), anemia 243 (aRR 1.49, 95% CI 1.21-1.82, P<0.001), kidney disorders (aRR 1.27, 95% CI 1.10-1.45, P=0.001) 244 and urinary disorders (aRR 1.40, 95% CI 1.20-1.63, P<0.001) (Figure 5A), whereas no association 245 246 was observed among patients with autoimmune disorders (eFigure 5 in Supplement 1). There was no difference in the coincidence of all comorbidities between $\alpha \tau^+$ samples (5, 0.46%) and $\alpha \tau^-$ sam-247
- 248 ples (69, 0.33%) (P=0.633).

To address potential biases arising from grouping and selecting major categories, we explored the 249 250 association between $\alpha \tau^+$ and individual ICD-10 codes. Across 276 individual ICD-10 codes and after correction for multiple comparisons, eight exhibited significant associations with $\alpha \tau^+$ (Figures 251 252 5B and C). These included "E61-deficiency of other nutrient elements" (aRR 2.22, 95% CI 1.54-3.06, P<0.001), "I74–arterial embolism and thrombosis" (aRR 2.09, 95% CI 1.40-2.94, P<0.001), 253 254 "N30-cystitis" (aRR 1.84, 95% CI 1.32-2.47, P<0.001), "I70-atherosclerosis" (aRR 1.57, 95% CI 1.29-1.89, P<0.001), "D50-iron deficiency anemia" (aRR 1.50, 95% CI 1.21-1.82, P<0.001), 255 256 "N39-other urinary disorders" (aRR 1.40, 95% CI 1.19-1.64, P<0.001), "B96-other bacterial agents as the cause of diseases" (aRR 1.40, 95% CI 1.17-1.66, P<0.001) and "N18-chronic kidney 257 disease" (aRR 1.38, 95% CI 1.18-1.60, P<0.001; Figure 5C). Conversely, we found no significant 258 259 negative association between tau autoreactivity and any ICD-10 codes that could suggest a de-260 creased risk for a specific disease in $\alpha \tau^+$ patients (Figure 5C). To verify relevant associations, we 261 used Bayesian logistic regression using logit-transformed EC₅₀ values (-logit[EC₅₀]) as a continuous outcome. All the previously referred eight ICD-10 codes showed positive associations with -262 $logit[EC_{50}]$ (eFigure 6). 263

264 To validate these conditions as significant associations with plasma MTBD-tau IgG autoantibodies, we examined the association between $\alpha \tau^+$ and 106 commonly requested laboratory parameters 265 266 using data available for 24,177 patients, independently of any ICD-10 classifiers. After correction for multiple comparisons, the laboratory markers "Leukocytes, urine", "Potassium" and "Urea" 267 were positively associated with tau autoimmunity (Figure 5D). The association with increasing 268 levels of urea and potassium suggests a link to kidney failure, whereas leukocytes in urine are a 269 270 feature of urinary tract infections. These findings support the hypothesis that anti-tau autoimmunity correlates with such disorders. Accordingly, the prevalence of chronic kidney disease was 271 12.4% in $\alpha \tau^{-}$ and 17.7% in $\alpha \tau^{+}$ patients, whereas that of other urinary disorders was 10.3% in $\alpha \tau^{-}$ 272 and 15.1% in $\alpha \tau^+$ patients (Figure 5E). 273

275 **DISCUSSION**

This study was designed to discover novel associations between autoreactivity to tau and human 276 277 diseases. This approach of "reverse immunopathology" is hypothesis-free: it does not pose constraints on the type of diseases that might result from anti-tau immunity. While the approach is 278 generally applicable to any autoantigen, its predictive power relies on the analysis of large patient 279 collectives, which in turn requires the development of high-throughput methods at reasonable cost. 280 We therefore miniaturized antibody detection to 3 µl/sample in 1,536-well microplates, allowing 281 to run 40,000 assays/24 hrs with minimal hands-on time. We performed >300,000 immunoassays 282 on >40,000 plasma samples for $\alpha \tau$ autoreactivity.²³⁻²⁵ Each sample was measured at eight dilution 283 points, enabling precise and unambiguous titer determinations.²³⁻²⁵. 284

Plasma at IgG were more prevalent in women and increased with age, reaching 7.6% in the cohort 285 of 90-99-year-olds. The specificity of $\alpha \tau^+$ plasma to MTBD-tau was high and was confirmed by 286 multiple assays including epitope mapping. The age- and sex-adjusted $\alpha \tau^+$ rate in hospital patients 287 was three-fold higher than in healthy blood donors and was 2.4 times higher than that of autoanti-288 bodies targeting other intracellular neuronal targets, suggesting a correlation with disease states.³⁶ 289 However, we did not find any association between $\alpha \tau^+$ and any neurological conditions including 290 neurodegenerative diseases, corroborating with reports of similar levels of plasma tau autoanti-291 bodies in AD patients and non-demented controls.³⁷ Instead, we uncovered a robust, specific as-292 sociation between $\alpha \tau^+$ positivity and kidney and urinary disorders. This was independently vali-293 294 dated by associations with higher prevalence of positive samples from the department of Nephrology, grouped kidney and urinary diseases, individual kidney and urinary diagnosis codes and re-295 296 lated clinical laboratory biomarkers, such as high serum urea and potassium and high urine leuko-297 cytes.

Seroepidemiological studies cannot establish causality: $\alpha \tau$ seropositivity could be a cause or a consequence of the clinical syndromes associated with it.³⁸ However, tau is expressed in extraneural tissues, including kidney podocytes and urinary bladder,²⁻⁵ and its ablation causes glomerular pathologies.³⁹ Besides raising the possibility that plasma $\alpha \tau$ autoantibodies might drive kidney pathologies, these findings suggest that such autoantibodies represent useful biomarkers of these diseases and that it will be important to monitor renal and urinary function in the current clinical trials of tau immunotherapy.⁴⁰⁻⁴²

305 Recent studies have explored the use of tau measurements in plasma as biomarkers for AD diagnosis and for monitoring its progression.^{9-12,33,43-47} However, we found that anti-MTBD-tau auto-306 antibodies could hinder tau detection in plasma by binding to epitopes recognized by commercial 307 biomarker immunoassays. This aligns with prior research indicating that both plasma anti-tau au-308 toantibodies and administered anti-tau antibodies can influence the dynamics of tau levels in 309 plasma.⁴⁸ Additionally, a recent community cohort study using an immunoassay for AD screening 310 311 revealed associations between plasma tau levels and numerous comorbidities, with chronic kidney disease showing one of the strongest associations.⁴⁹ These results imply that the presence of anti-312 tau autoantibodies in plasma might impact the effectiveness of plasma tau as an AD biomarker, 313 particularly for patients with kidney or urinary diseases. This consideration may become crucial 314 as plasma tau levels move toward routine clinical use in AD diagnosis. 315

316

317 Limitations

Our large-scale assessment of plasma tau autoimmunity has certain limitations. Firstly, most sam-318 319 ples analyzed in our study came from a university hospital cohort, implying a bias towards com-320 plex pathologies and polymorbidities. To account for this, we included a vast collection of samples from healthy blood donors. Secondly, our study is confined to two sites within a single region with 321 322 approximately 1,500,000 inhabitants whose ethnic composition was not thoroughly examined. Additionally, a direct comparison of the prevalence of plasma anti-tau antibodies in these two cohorts 323 324 may potentially suffer from variations in materials, collection methods (e.g. addition of heparin that may cause aggregation of MTBD-tau), and handling processes at the two different sites. 325 326 Thirdly, our study is restricted to the analysis of specific disease groups, the absence of a replication cohort and a longitudinal disease cohort that would allow for verification, examining a time 327 328 course, origin, and causal role of these autoantibodies. Finally, we used bacterially expressed 329 MTBD-tau as target, thereby excluding full-length or post-translationally modified tau epitopes. 330 As a result, plasma anti-tau autoantibodies associated with AD pathology might be missed, and 331 our methodology may underestimate the prevalence of total anti-tau autoantibodies.

332

333 Conclusions

- 334 Our study identified a high seroprevalence of anti-MTBD-tau IgG autoantibodies in both plasma
- 335 samples from university hospital patients and healthy blood donors. Tau autoimmunity is associ-
- ated with female sex, older age and previously unrecognized extraneural diseases. These findings
- 337 point to unrecognized roles for tau and anti-tau autoantibodies in extraneural pathologies and call
- 338 for attentive clinical monitoring of such diseases in clinical trials of tau-targeting therapies and in
- the use of plasma tau as a biomarker of disease.

340 **References**

3411.Gu Y, Oyama F, Ihara Y. Tau is widely expressed in rat tissues. J Neurochem. Sep3421996;67(3):1235-44. doi:10.1046/j.1471-4159.1996.67031235.x

3432.Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human344proteome. Science. Jan 23 2015;347(6220):1260419. doi:10.1126/science.1260419

345 3. Sotiropoulos I, Galas MC, Silva JM, et al. Atypical, non-standard functions of the 346 microtubule associated Tau protein. *Acta Neuropathol Commun*. Nov 2017;5(1):91. 347 doi:10.1186/s40478-017-0489-6

4. Rinschen MM, Gödel M, Grahammer F, et al. A Multi-layered Quantitative In Vivo Expression Atlas of the Podocyte Unravels Kidney Disease Candidate Genes. *Cell Rep.* 05 2018;23(8):2495-2508. doi:10.1016/j.celrep.2018.04.059

Ho KH, Yang X, Osipovich AB, et al. Glucose Regulates Microtubule Disassembly and the
 Dose of Insulin Secretion via Tau Phosphorylation. *Diabetes*. Sep 2020;69(9):1936-1947.
 doi:10.2337/db19-1186

- 6. Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. *Proc Natl Acad Sci U S A*. Jun 1986;83(11):4044-8. doi:10.1073/pnas.83.11.4044
- Joachim CL, Morris JH, Kosik KS, Selkoe DJ. Tau antisera recognize neurofibrillary tangles
 in a range of neurodegenerative disorders. *Ann Neurol*. Oct 1987;22(4):514-20.
 doi:10.1002/ana.410220411
- Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. Association of Amyloid and Tau With
 Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurol. Aug 1
 2019;76(8):915-924. doi:10.1001/jamaneurol.2019.1424
- 363 9. Mattsson N, Zetterberg H, Janelidze S, et al. Plasma tau in Alzheimer disease. *Neurology*.
 364 Oct 25 2016;87(17):1827-1835. doi:10.1212/WNL.00000000003246
- Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease:
 relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal
 progression to Alzheimer's dementia. *Nat Med.* 03 2020;26(3):379-386. doi:10.1038/s41591 020-0755-1
- Mielke MM, Hagen CE, Wennberg AMV, et al. Association of Plasma Total Tau Level With
 Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on
 Aging. JAMA Neurol. 09 01 2017;74(9):1073-1080. doi:10.1001/jamaneurol.2017.1359

Palmqvist S, Tideman P, Mattsson-Carlgren N, et al. Blood Biomarkers to Detect Alzheimer
Disease in Primary Care and Secondary Care. JAMA. Jul 28 2024;doi:10.1001/jama.2024.13855

13. Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. *Nat Rev Neurol.* 07 2018;14(7):399-415. doi:10.1038/s41582-018-0013-z

- 37614.Rothstein TL. Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the377Aged. Front Immunol. 2016;7:127. doi:10.3389/fimmu.2016.00127
- 37815.Lutz HU, Binder CJ, Kaveri S. Naturally occurring auto-antibodies in homeostasis and379disease. Trends Immunol. Jan 2009;30(1):43-51. doi:10.1016/j.it.2008.10.002

380 16. Jaycox JR, Dai Y, Ring AM. Decoding the autoantibody reactome. *Science*. Feb 16
 381 2024;383(6684):705-707. doi:10.1126/science.abn1034

17. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR)
encephalitis in children and adolescents. *Ann Neurol*. Jul 2009;66(1):11-8. doi:10.1002/ana.21756
18. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of
neuromyelitis optica: distinction from multiple sclerosis. *Lancet*. 2004 Dec 11-17
2004;364(9451):2106-12. doi:10.1016/S0140-6736(04)17551-X

Ferrero J, Williams L, Stella H, et al. First-in-human, double-blind, placebo-controlled,
 single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease.
 Alzheimers Dement (N Y). Sep 2016;2(3):169-176. doi:10.1016/j.trci.2016.06.002

Bartos A, Fialová L, Švarcová J. Lower Serum Antibodies Against Tau Protein and Heavy
 Neurofilament in Alzheimer's Disease. *J Alzheimers Dis*. 2018;64(3):751-760. doi:10.3233/JAD 180039

393 21. Kronimus Y, Albus A, Balzer-Geldsetzer M, et al. Naturally Occurring Autoantibodies
 394 against Tau Protein Are Reduced in Parkinson's Disease Dementia. *PLoS One*.
 395 2016;11(11):e0164953. doi:10.1371/journal.pone.0164953

Bartos A, Fialova L, Svarcova J. Lower Serum Antibodies Against Tau Protein and Heavy
 Neurofilament in Alzheimer's Disease. *J Alzheimers Dis.* 2018;64(3):751-760. doi:10.3233/JAD 180039

23. Emmenegger M, De Cecco E, Lamparter D, et al. Continuous population-level monitoring
of SARS-CoV-2 seroprevalence in a large European metropolitan region. *iScience*. Feb 17
2023;26(2):105928. doi:10.1016/j.isci.2023.105928

40224.Senatore A, Frontzek K, Emmenegger M, et al. Protective anti-prion antibodies in human403immunoglobulin repertoires.*EMBO Mol Med.*Sep 7 2020;12(9):e12739.404doi:10.15252/emmm.202012739

25. Emmenegger M, Zografou C, Yile D, et al. The Cystic Fibrosis Transmembrane Regulator
Controls Tolerogenic Responses to Food Allergens in Mice and Humans. *medRxiv*.
2024;doi:<u>https://doi.org/10.1101/2024.06.17.24309019</u>

408 26. Organization WH. ICD-10 : international statistical classification of diseases and related 409 health problems revision, 2nd : tenth ed. World Health Organization. https://iris.who.int/handle/10665/42980. 2004. 410

411 27. de Silva R, Lashley T, Gibb G, et al. Pathological inclusion bodies in tauopathies contain 412 distinct complements of tau with three or four microtubule-binding repeat domains as 413 demonstrated by new specific monoclonal antibodies. *Neuropathol Appl Neurobiol*. Jun 414 2003;29(3):288-302. doi:10.1046/j.1365-2990.2003.00463.x

415 28. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and 416 clinical trials of common outcomes. *Am J Epidemiol*. May 2003;157(10):940-3. 417 doi:10.1093/aje/kwg074

418 29. Diaz-Quijano FA. A simple method for estimating relative risk using logistic regression.
419 *BMC Med Res Methodol*. Feb 2012;12:14. doi:10.1186/1471-2288-12-14

420 **30**. *RStudio: Integrated Development Environment for R*. RStudio, PBC; 2021.

31. Donoghoe MW, Marschner IC. Logbin: An R Package for Relative Risk Regression Using
 the Log-Binomial Model. *Journal of Statistical Software* 2018;86(21)

423 32. Apetri A, Crespo R, Juraszek J, et al. A common antigenic motif recognized by naturally
424 occurring human V. *Acta Neuropathol Commun*. 05 2018;6(1):43. doi:10.1186/s40478-018-0543425 z

426 33. Pase MP, Beiser AS, Himali JJ, et al. Assessment of Plasma Total Tau Level as a Predictive 427 Biomarker for Dementia and Related Endophenotypes. *JAMA Neurol*. 05 2019;76(5):598-606.

428 doi:10.1001/jamaneurol.2018.4666

429 34. Barini E, Plotzky G, Mordashova Y, et al. Tau in the brain interstitial fluid is fragmented 430 and seeding-competent. *Neurobiol Aging*. Jan 2022;109:64-77.

431 doi:10.1016/j.neurobiolaging.2021.09.013

432 35. Donoghoe MW, Marschner IC. logbin: An R Package for Relative Risk Regression Using the
433 Log-Binomial Model. *Journal of Statistical Software*. Sep 4, 2018 2018;86(9):21.
434 doi:10.18637/jss.v086.i09

43536.Dahm L, Ott C, Steiner J, et al. Seroprevalence of autoantibodies against brain antigens in436health and disease. Ann Neurol. Jul 2014;76(1):82-94. doi:10.1002/ana.24189

437 37. Yu G, Chen J, Xu Y, et al. Generation of goats lacking prion protein. *Mol Reprod Dev.* Jan
438 2009;76(1):3. doi:10.1002/mrd.20960

38. Tsuboi Y, Uitti RJ, Delisle MB, et al. Clinical features and disease haplotypes of individuals
with the N279K tau gene mutation: a comparison of the pallidopontonigral degeneration kindred

441 and a French family. *Arch Neurol*. Jun 2002;59(6):943-50. doi:10.1001/archneur.59.6.943

- 39. Vallés-Saiz L, Peinado-Cahuchola R, Ávila J, Hernández F. Microtubule-associated protein
 tau in murine kidney: role in podocyte architecture. *Cell Mol Life Sci.* Jan 27 2022;79(2):97.
 doi:10.1007/s00018-021-04106-z
- 445 40. Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM. Tau-targeting therapies for 446 Alzheimer disease: current status and future directions. *Nat Rev Neurol*. Dec 2023;19(12):715-447 736. doi:10.1038/s41582-023-00883-2
- 448 41. NCT05269394 ClinicalTrial.gov, NCT05269394, Dominantly Inherited Alzheimer Network 449 Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments 450 in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation 451 (DIAN-TU),
- 452 (https://clinicaltrials.gov/study/NCT05269394?cond=Alzheimer%20Disease&term=E2814&rank
 453 =1) (2023).
- 454 **42**. Barton ME, Van Den Steen B, Van Tricht HLG, et al. Update on the TOGETHER study: a 455 patient- and investigator-blind, randomized, placebo-controlled study evaluating the efficacy,
- 456 safety and tolerability of bepranemab, UCB0107, in prodromal-to-mild Alzheimer's disease.
 457 Alzheimer's & Dementia. 2022;18(S10):e068973.

43. Moscoso A, Grothe MJ, Ashton NJ, et al. Longitudinal Associations of Blood
Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer
Disease. JAMA Neurol. Apr 01 2021;78(4):396-406. doi:10.1001/jamaneurol.2020.4986

461 44. Barthélemy NR, Li Y, Joseph-Mathurin N, et al. A soluble phosphorylated tau signature
462 links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nat*463 *Med.* 03 2020;26(3):398-407. doi:10.1038/s41591-020-0781-z

464 45. Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for 465 Alzheimer's disease: a diagnostic performance and prediction modelling study using data from 466 four prospective cohorts. *Lancet Neurol*. 05 2020;19(5):422-433. doi:10.1016/S1474-467 4422(20)30071-5

468 46. Park JC, Han SH, Yi D, et al. Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition
469 and neurodegeneration in Alzheimer's disease. *Brain*. 03 01 2019;142(3):771-786.
470 doi:10.1093/brain/awy347

47. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phosphotau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA*. Aug 25
2020;324(8):772-781. doi:10.1001/jama.2020.12134

474 48. Yanamandra K, Patel TK, Jiang H, et al. Anti-tau antibody administration increases plasma 475 transgenic mice and patients with tauopathy. Sci Med. tau in Transl 04 476 2017;9(386)doi:10.1126/scitranslmed.aal2029

- 477 49. Mielke MM, Dage JL, Frank RD, et al. Performance of plasma phosphorylated tau 181 and
 478 217 in the community. *Nat Med*. Jul 2022;28(7):1398-1405. doi:10.1038/s41591-022-01822-2
- 479

480 Acknowledgments:

The authors wish to thank the hospital patients and blood donors for their generous altruistic con-481 tributions to this study. Imaging was performed with equipment maintained by the Center for Mi-482 483 croscopy and Image Analysis, University of Zurich. We thank Prof. Rohan de Silva (UCL Queen Square Institute of Neurology, London, UK) for providing the purified anti-MTBD-tau antibody 484 RD4. We thank Dr. Marco Losa. Magdalena Bialkowska, Lisa Caflisch, Berre Doğançay, Julie 485 Domange, Marigona Imeri, Lorène Mottier, Rea Müller, Antonella Rosati, Dezirae Schneider, and 486 Anne Wiedmer for help with the high-throughput assays. Insightful advice about programming in 487 R software was provided by Reto Guadagnini. Imaging was performed with equipment from the 488 489 Center for Microscopy and Image Analysis, University of Zurich. 490

491

492 **Funding:**

- 493 University of Zürich, Candoc grant FK-19-025 (ADM)
- 494 Swiss Personalised Health Network, SPHN, driver project grant 2017DRI17 (AA)
- 495 Swiss National Foundation SNF (SNSF grant ID 179040 and grant ID 207872, Sinergia grant ID
- 496 183563) (AA)
- 497 European Research Council ERC Prion2020, 670958 (AA)
- 498 Nomis Foundation (AA)
- 499 Innovation Fund of the University Hospital Zurich (INOV00096) (AA)
- 500 University Hospital Zurich Foundation grant USZF27101 (with contributions of the NOMIS Foun-
- 501 dation, the Schwyzer Winiker Stiftung, and the Baugarten Stiftung, AA, ME)

- 502 HMZ ImmunoTarget grant, Stiftung Neuropath and GELU Foundation (AA)
- 503 Michael J. Fox Foundation (grant ID MJFF-020710 and MJFF-021073) (SH).
- 504

505 Author contributions:

Conceived and designed the experiments: ADM, SH, AA. Supervised the study: SH, AA. Per-506 507 formed tau protein purification: ADM, EDC, JG. Performed tau microELISA automated screen: ADM, ME. Performed amyloid-ß pyroglutamate and cellular prion protein microELISA auto-508 mated screen: MC, KF, ME. Maintained microELISA automated platform: ME. Performed puri-509 fication, validation and characterization of anti-tau autoantibodies: ADM, JG. Maintained the clin-510 ical database: ME, AC. Performed data analysis and visualization: ADM. Wrote the first draft of 511 manuscript: ADM. Corrected and advised on subsequent versions of the manuscript: ADM, ME, 512 513 SH, AA. All authors reviewed and approved the final version of the manuscript and consented to be accountable for the work. 514

515

516 **Competing interests:**

ADM has received a research grant from University of Zurich; KF has received research grants 517 from Ono Pharmaceuticals and Theodor Ida Herzog Egli Stiftung, consulting fees from Acumen 518 519 Collective and Ionis Pharmaceuticals, support for attending meetings/travel from Euro-CNS and 520 has participated on the Advisory Board of Mabylon AG; AA has received research grants from the 521 Swiss Personalized Health Network, Swiss National Foundation, European Research Council and Nomis Foundation and is a member of the Board of Directors of Mabylon AG. Mabylon AG pro-522 523 duces therapeutic human antibodies. Mabylon AG had no insight and no influence on the current 524 study. All authors report no other relationships or activities that could appear to have influenced the submitted work. 525

526

527 Data and materials availability:

528 Data and materials will be shared upon approval by the Cantonal Ethics Committee where neces-529 sary.





Figure 1. Study overview and seroprevalence of anti-MTBD-tau IgG autoantibodies. A. 532 533 Flowchart of the study design. **B.-C.** Distribution of $-\log_{10}(EC_{50})$ values obtained from the micro-ELISA screen of hospital (B) and blood donor (C) plasma samples. D. aRR and 95% CI (I bars) 534 535 for the detection of anti-tau autoantibodies in hospital and blood-bank plasma samples. E. Replicability of microELISA duplicates with independent estimation of the $-\log_{10}(EC_{50})$ values. Dashed 536 lines: cut-off value of $-\log_{10}(EC_{50}) = 1.8$. F. $-\log_{10}(EC_{50})$ values of samples tested by microELISA 537 against MTBD-tau and amyloid-ß pyroglutamate. G. Same as shown in (F), but for samples tested 538 against MTBD-tau and PrP^C. 539

540

531



Figure 2. Natural $\alpha \tau$ **autoantibodies impair tau detection. A.** Principle of the competition sandwich ELISA. **B-C.** Competitive sandwich ELISA to assess the ability of purified anti-tau autoantibodies with matching (P4-P6) and non-matching (P2 and P3) epitopes to the commercial detection antibody, ab64193, to impair the detection of free tau⁴⁴¹ spiked in plasma (dark blue). Serial dilutions of purified anti-tau antibodies are shown in (B) and binding at highest anti-tau antibody concentrations in (C).

- 549
- 550
- 551





553Figure 3. Demographic characteristics of hospital patients' cohort. A. Age and sex pyramid554of positive and negative individuals. B. Percentage of positives among hospital patients across555decadic age groups. The numbers on top of each bar correspond to the positivity rates. χ^2 test for556trend in proportions. C. RR ± 95% CI for $\alpha \tau^+$ autoantibodies according to sex and age groups.557Asterisks: P < 0.05 after Bonferroni correction. D. Break-down of samples by clinical department.</td>558Asterisks: P < 0.05 (two-proportions z-test with Bonferroni correction). E. aRR ± 95% CI for $\alpha \tau^+$ 559samples by clinical department. Asterisks: P < 0.05 after Bonferroni correction.</td>

560





Figure 4. aRR of MTBD-tau-autoreactivity for major groups of neurological disorders and reactivity profiles for AD screen. **A.** aRR and 95% CI (I bars) for $\alpha \tau^+$ autoantibodies according to different groups of neurological disorders. No P values remained significant after Bonferroni correction. **B.** Boxplots showing the 25th, 50th (median) and 75th percentiles of the reactivity profiles for AD and control patients (Mann-Whitney U test).



569

570 Figure 5. Association of MTBD-tau IgG autoantibodies with systemic disorders and clinical **laboratory data.** A. aRR \pm 95% CI (bars) for $\alpha \tau^+$ autoantibodies grouped 27 different main sys-571 temic clinical conditions. Asterisks: P < 0.05 after Bonferroni correction. **B.** $-\log_{10}(P \text{ value})$ of the 572 log-binomial regression for the presence of plasma MTBD-tau IgG autoantibodies for 276 disor-573 ders according to ICD-10 codes and adjusted for age and sex. Triangles pointing upwards and 574 downwards: positive and coefficients, respectively; gray dashed line: P < 0.05 after Bonferroni 575 correction (here and henceforth). P values significant after Bonferroni adjustment are labelled with 576 577 the ICD codes. C. Bayesian logistic regression adjusted for age and sex on ICD-10 codes signifi-578 cantly associated in B. and using $-\log_{10}(EC_{50})$ as continuous outcome (odds ratio $\pm 95\%$ credible

579 intervals). This analysis confirms the positive association of these ICD-10 codes with $\alpha\tau$ reactivity

580 (from B). **D.** -log₁₀(P value) of the log-binomial regression for the presence of plasma MTBD-tau

581 IgG autoantibodies and clinical laboratory parameters. P values significant after Bonferroni ad-

582 justment are labelled with the ICD codes. The gray dashed line indicates the significance level

after Bonferroni correction (<0.05/106=0.00047). eGFR CKD-EPI 2009: estimated glomerular fil-

- tration rate using the Chronic Kidney Disease Epidemiology Collaboration 2009 equation; eGFR
- 585 BIS1: estimated glomerular filtration rate using the older adults Berlin Initiative Study 1 equation.
- 586 INR: international normalized ratio. LDL: low-density lipoprotein. HDL: high-density lipoprotein.
- 587 **E.** Calculated prevalence of different ICD-10 codes in the total cohort (dark blue), $\alpha \tau^{-}$ (intermediate
- 588 blue) and $\alpha \tau^+$ samples (light blue).
- 589